Fractyl Health (GUTS) Share-based Compensation (2023 - 2026)
Fractyl Health's (GUTS) quarterly Share-based Compensation came in at $2.5 million in Q1 2026, up 80.01% YoY from $1.4 million in Q1 2025, and up 36.44% on a QoQ basis from $1.9 million in Q4 2025.
Fractyl Health (GUTS) Share-based Compensation (2023 - 2026) Analysis & Trends
Fractyl Health (GUTS) has 4 years of Share-based Compensation data on file, last reported at $2.5 million in Q1 2026.
- Quarterly Share-based Compensation rose 80.01% year-over-year to $2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.8 million (down 26.43% YoY) and the FY2025 annual result came in at $19.1 million, up 32.4% from the prior year.
- Share-based Compensation climbed to $2.5 million in Q1 2026, from $1.9 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $5.2 million in Q1 2024 to a low of $857000.0 in Q1 2023.
- A 4-year average of $2.1 million and a median of $1.8 million in 2025 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2024 — Share-based Compensation surged 508.75% — and 2025, when it tumbled 73.05%.
- Tracing GUTS's Share-based Compensation over 4 years: stood at $1.3 million in 2023, then jumped by 127.19% to $2.9 million in 2024, then slumped by 36.01% to $1.9 million in 2025, then jumped by 36.44% to $2.5 million in 2026.
- The last three Share-based Compensation figures came in at $2.5 million (Q1 2026), $1.9 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.70 Bn | 131.85 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.36 Bn | 60.18 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.15 Bn | 54.01 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.88 Bn | 28.57 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | - |
| 10 | Fractyl Health | 128.47 Mn | 128.47 Mn | - | 2.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.50 Mn |
| Jun 30, 2026 | 2.50 Mn |
| Mar 31, 2026 | 2.53 Mn |
| Mar 31, 2026 | 2.53 Mn |
| Dec 31, 2025 | 1.86 Mn |
| Dec 31, 2025 | 1.86 Mn |
| Sep 30, 2025 | 1.64 Mn |
| Sep 30, 2025 | 1.64 Mn |
| Jun 30, 2025 | 1.79 Mn |
| Jun 30, 2025 | 1.79 Mn |
| Mar 31, 2025 | 1.41 Mn |
| Mar 31, 2025 | 1.41 Mn |
| Dec 31, 2024 | 2.90 Mn |
| Dec 31, 2024 | 2.90 Mn |
| Sep 30, 2024 | 2.52 Mn |
| Sep 30, 2024 | 2.52 Mn |
| Jun 30, 2024 | 3.79 Mn |
| Jun 30, 2024 | 3.79 Mn |
| Mar 31, 2024 | 5.22 Mn |
| Mar 31, 2024 | 5.22 Mn |